The allergic rhinitis market size has grown steadily in recent years. It will grow from $15.69 billion in 2025 to $16.28 billion in 2026 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to increasing awareness of allergies, rising environmental allergens exposure, adoption of traditional antihistamines and corticosteroids, growth of hospital pharmacy networks, development of diagnostic skin testing methods.
The allergic rhinitis market size is expected to see steady growth in the next few years. It will grow to $19.58 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advances in immunotherapy treatments, rising demand for personalized allergy management, increasing adoption of online pharmacies, technological improvements in ige rast and blood tests, expansion of global allergy treatment markets. Major trends in the forecast period include rising prevalence of allergic rhinitis worldwide, increased use of immunotherapy and personalized treatments, growing adoption of nasal corticosteroids and antihistamines, expansion of online pharmacies and e-commerce distribution, enhanced diagnostic testing including skin and ige rast tests.
Rising levels of air pollution and climate change are expected to drive the growth of the allergic rhinitis market in the coming years. Air pollution refers to the presence of harmful substances in the Earth's atmosphere that can negatively impact human health, the environment, and air quality. Climate change refers to long-term shifts in the Earth's climate patterns, including temperature, precipitation, and other climatic factors. Air pollution has increasingly been recognized as a major environmental contributor to the prevalence and worsening of allergic rhinitis, highlighting the complex relationship between air quality and respiratory health. For instance, in August 2024, according to the United States Environmental Protection Agency, a US-based government agency, approximately 66 million tons of pollutants were released into the atmosphere across the United States in 2023. Therefore, rising air pollution levels and climate change are fueling the allergic rhinitis market.
Major companies operating in the allergic rhinitis market are focusing on developing innovative products, such as combination allergy therapies, to provide multi-pathway symptom relief and improve long-term management of allergic conditions. A combination allergy therapy is a dual-action formulation that combines different classes of active ingredients to deliver broader and more effective control of allergy-related inflammation. For instance, in October 2025, Cadila Pharmaceuticals, an India-based pharmaceutical manufacturer, launched Dlorfast-M Tablets. The formulation combines Desloratadine and Montelukast to block both histamine- and leukotriene-mediated pathways, offering stronger and more comprehensive relief than either agent alone. Its once-daily dosing enhances treatment adherence while expanding therapeutic options for patients with allergic rhinitis and urticaria.
In March 2024, Shionogi & Co., Ltd., a Japan-based provider of pharmaceuticals and innovative therapies, entered into an option agreement to acquire the exclusive global research, development, and commercialization rights to FPP004X from FunPep Co., Ltd., for $1.9 million. Through this agreement, Shionogi aims to strengthen its allergic rhinitis pipeline by adding a novel anti-IgE antibody-inducing peptide vaccine designed to provide long-lasting relief from seasonal allergic rhinitis. FunPep Co., Ltd. is a Japan-based biotechnology company developing peptide-based therapeutics, including FPP004X, an early-stage vaccine candidate targeting IgE-mediated pollen allergy.
Major companies operating in the allergic rhinitis market are Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Menarini Group, Perrigo Company plc, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Limited, Zydus Lifesciences Ltd., Lupin Limited, Glenmark Pharma Ltd., Almirall S.A., Kyowa Kirin Co. Ltd., Hanmi Pharmaceutical Co. Ltd.
North America was the largest region in the allergic rhinitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allergic rhinitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergic rhinitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the allergic rhinitis market by increasing the cost of imported allergy drugs, immunotherapy kits, and diagnostic testing equipment. Segments such as corticosteroids, monoclonal antibodies, and RAST test kits are most impacted, particularly in North America, Europe, and Asia-Pacific regions reliant on imports. This has led to higher treatment costs and delayed availability in certain regions. On the positive side, tariffs are encouraging local production, boosting domestic pharmaceutical manufacturing, and supporting regional self-reliance in allergy treatments.
The allergic rhinitis market research report is one of a series of new reports that provides allergic rhinitis market statistics, including allergic rhinitis industry global market size, regional shares, competitors with a allergic rhinitis market share, detailed allergic rhinitis market segments, market trends and opportunities, and any further data you may need to thrive in the allergic rhinitis industry. This allergic rhinitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Allergic rhinitis is an allergic reaction causing nasal inflammation triggered by allergens such as pollen, dust, mold, or animal dander, leading to sneezing, nasal congestion, itchy nose, and sore throat. It is managed with a range of allergy medications in various dosage forms to help relieve symptoms.
The main types of allergic rhinitis include seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis. Seasonal allergic rhinitis (SAR) is a type characterized by the rapid and recurring onset and resolution of symptoms, often linked to pollen exposure. Treatments include antihistamines, corticosteroids, immunotherapy, decongestants, and others, supported by diagnostic tests such as skin tests, IgE radioallergosorbent tests, and complete blood counts. Medications are administered through various routes, including oral and nasal, and are distributed via hospital pharmacies, retail pharmacies, and online stores.
The allergic rhinitis market consists of revenues earned by entities by providing treatments such as alternative therapies, surgeries and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The allergic rhinitis market also includes sales of allergy pills and injections that are used for the treatment of the disease. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The allergic rhinitis market size is expected to see steady growth in the next few years. It will grow to $19.58 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advances in immunotherapy treatments, rising demand for personalized allergy management, increasing adoption of online pharmacies, technological improvements in ige rast and blood tests, expansion of global allergy treatment markets. Major trends in the forecast period include rising prevalence of allergic rhinitis worldwide, increased use of immunotherapy and personalized treatments, growing adoption of nasal corticosteroids and antihistamines, expansion of online pharmacies and e-commerce distribution, enhanced diagnostic testing including skin and ige rast tests.
Rising levels of air pollution and climate change are expected to drive the growth of the allergic rhinitis market in the coming years. Air pollution refers to the presence of harmful substances in the Earth's atmosphere that can negatively impact human health, the environment, and air quality. Climate change refers to long-term shifts in the Earth's climate patterns, including temperature, precipitation, and other climatic factors. Air pollution has increasingly been recognized as a major environmental contributor to the prevalence and worsening of allergic rhinitis, highlighting the complex relationship between air quality and respiratory health. For instance, in August 2024, according to the United States Environmental Protection Agency, a US-based government agency, approximately 66 million tons of pollutants were released into the atmosphere across the United States in 2023. Therefore, rising air pollution levels and climate change are fueling the allergic rhinitis market.
Major companies operating in the allergic rhinitis market are focusing on developing innovative products, such as combination allergy therapies, to provide multi-pathway symptom relief and improve long-term management of allergic conditions. A combination allergy therapy is a dual-action formulation that combines different classes of active ingredients to deliver broader and more effective control of allergy-related inflammation. For instance, in October 2025, Cadila Pharmaceuticals, an India-based pharmaceutical manufacturer, launched Dlorfast-M Tablets. The formulation combines Desloratadine and Montelukast to block both histamine- and leukotriene-mediated pathways, offering stronger and more comprehensive relief than either agent alone. Its once-daily dosing enhances treatment adherence while expanding therapeutic options for patients with allergic rhinitis and urticaria.
In March 2024, Shionogi & Co., Ltd., a Japan-based provider of pharmaceuticals and innovative therapies, entered into an option agreement to acquire the exclusive global research, development, and commercialization rights to FPP004X from FunPep Co., Ltd., for $1.9 million. Through this agreement, Shionogi aims to strengthen its allergic rhinitis pipeline by adding a novel anti-IgE antibody-inducing peptide vaccine designed to provide long-lasting relief from seasonal allergic rhinitis. FunPep Co., Ltd. is a Japan-based biotechnology company developing peptide-based therapeutics, including FPP004X, an early-stage vaccine candidate targeting IgE-mediated pollen allergy.
Major companies operating in the allergic rhinitis market are Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Menarini Group, Perrigo Company plc, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Limited, Zydus Lifesciences Ltd., Lupin Limited, Glenmark Pharma Ltd., Almirall S.A., Kyowa Kirin Co. Ltd., Hanmi Pharmaceutical Co. Ltd.
North America was the largest region in the allergic rhinitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allergic rhinitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergic rhinitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the allergic rhinitis market by increasing the cost of imported allergy drugs, immunotherapy kits, and diagnostic testing equipment. Segments such as corticosteroids, monoclonal antibodies, and RAST test kits are most impacted, particularly in North America, Europe, and Asia-Pacific regions reliant on imports. This has led to higher treatment costs and delayed availability in certain regions. On the positive side, tariffs are encouraging local production, boosting domestic pharmaceutical manufacturing, and supporting regional self-reliance in allergy treatments.
The allergic rhinitis market research report is one of a series of new reports that provides allergic rhinitis market statistics, including allergic rhinitis industry global market size, regional shares, competitors with a allergic rhinitis market share, detailed allergic rhinitis market segments, market trends and opportunities, and any further data you may need to thrive in the allergic rhinitis industry. This allergic rhinitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Allergic rhinitis is an allergic reaction causing nasal inflammation triggered by allergens such as pollen, dust, mold, or animal dander, leading to sneezing, nasal congestion, itchy nose, and sore throat. It is managed with a range of allergy medications in various dosage forms to help relieve symptoms.
The main types of allergic rhinitis include seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis. Seasonal allergic rhinitis (SAR) is a type characterized by the rapid and recurring onset and resolution of symptoms, often linked to pollen exposure. Treatments include antihistamines, corticosteroids, immunotherapy, decongestants, and others, supported by diagnostic tests such as skin tests, IgE radioallergosorbent tests, and complete blood counts. Medications are administered through various routes, including oral and nasal, and are distributed via hospital pharmacies, retail pharmacies, and online stores.
The allergic rhinitis market consists of revenues earned by entities by providing treatments such as alternative therapies, surgeries and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The allergic rhinitis market also includes sales of allergy pills and injections that are used for the treatment of the disease. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Allergic Rhinitis Market Characteristics
3. Allergic Rhinitis Market Supply Chain Analysis
4. Global Allergic Rhinitis Market Trends and Strategies
5. Allergic Rhinitis Market Analysis of End Use Industries
7. Global Allergic Rhinitis Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Allergic Rhinitis Total Addressable Market (TAM) Analysis for the Market
9. Allergic Rhinitis Market Segmentation
10. Allergic Rhinitis Market Regional and Country Analysis
11. Asia-Pacific Allergic Rhinitis Market
12. China Allergic Rhinitis Market
13. India Allergic Rhinitis Market
14. Japan Allergic Rhinitis Market
15. Australia Allergic Rhinitis Market
16. Indonesia Allergic Rhinitis Market
17. South Korea Allergic Rhinitis Market
18. Taiwan Allergic Rhinitis Market
19. South East Asia Allergic Rhinitis Market
20. Western Europe Allergic Rhinitis Market
21. UK Allergic Rhinitis Market
22. Germany Allergic Rhinitis Market
23. France Allergic Rhinitis Market
24. Italy Allergic Rhinitis Market
25. Spain Allergic Rhinitis Market
26. Eastern Europe Allergic Rhinitis Market
27. Russia Allergic Rhinitis Market
28. North America Allergic Rhinitis Market
29. USA Allergic Rhinitis Market
30. Canada Allergic Rhinitis Market
31. South America Allergic Rhinitis Market
32. Brazil Allergic Rhinitis Market
33. Middle East Allergic Rhinitis Market
34. Africa Allergic Rhinitis Market
36. Allergic Rhinitis Market Competitive Landscape and Company Profiles
37. Allergic Rhinitis Market Other Major and Innovative Companies
40. Allergic Rhinitis Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Allergic Rhinitis Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses allergic rhinitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for allergic rhinitis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The allergic rhinitis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis; Occupational Allergic Rhinitis2) By Treatment: Antihistamines; Corticosteroids; Immunotherapy; Decongestants; Other Treatments
3) By Test: Skin Test; IgE Radioallergosorbent (RAST) Test
4) By Route Of Administration: Oral; Nasal; Other Route Of Administration
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Stores
Subsegments:
1) By Seasonal Allergic Rhinitis: Pollen Allergy; Mold Allergy2) By Perennial Allergic Rhinitis: Dust Mite Allergy; Pet Allergy; Mold Allergy
3) By Occupational Allergic Rhinitis: Chemical Allergens; Biological Allergens
Companies Mentioned: Merck and Co. Inc.; Bayer AG; Novartis AG; Sanofi-Aventis LLC.; AstraZeneca PLC; GlaxoSmithKline plc.; Boehringer Ingelheim International GmbH; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Limited; Menarini Group; Perrigo Company plc; Dr. Reddy's Laboratories Ltd.; Hikma Pharmaceuticals PLC; Cipla Limited; Zydus Lifesciences Ltd.; Lupin Limited; Glenmark Pharma Ltd.; Almirall S.A.; Kyowa Kirin Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Allergic Rhinitis market report include:- Merck and Co. Inc.
- Bayer AG
- Novartis AG
- Sanofi-Aventis LLC.
- AstraZeneca PLC
- GlaxoSmithKline plc.
- Boehringer Ingelheim International GmbH
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Limited
- Menarini Group
- Perrigo Company plc
- Dr. Reddy's Laboratories Ltd.
- Hikma Pharmaceuticals PLC
- Cipla Limited
- Zydus Lifesciences Ltd.
- Lupin Limited
- Glenmark Pharma Ltd.
- Almirall S.A.
- Kyowa Kirin Co. Ltd.
- Hanmi Pharmaceutical Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 16.28 Billion |
| Forecasted Market Value ( USD | $ 19.58 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
